SIMU, which I have already put on this thread, has news out this am. Now, it sounds like we are going to have a very good 4th qtr...on top of .10 for the first 9mo that's going to make for a records year in all respects for SIMU. Stock has traded much higher than present 1.45. Remember, only 3.4m outstanding shares. So if you want the benefit of the pop when year end is announced, or when the prelim is announced next week, you are going to have to buy it now.:
B: Simulations Plus Sells Multi-Year License for GastroPlus; Fi
B: Simulations Plus Sells Multi-Year License for GastroPlus; First 5-Year
Subscription Contributes to Another Record Quarter
LANCASTER, Calif., Aug 29, 2002 (BUSINESS WIRE) -- Simulations Plus, Inc.
(OTCBB:SIMU.OB), (www.simulations-plus.com), the leading provider of ADME neural
net and absorption simulation software for pharmaceutical discovery and
development, announced today that it has sold a 5-year license for its
GastroPlus(TM) drug absorption software to a leading, advanced drug delivery
company serving the pharmaceutical industry. Financial terms were not disclosed,
but the Company indicated that this sale has resulted in yet another new record
quarter.
"This sale was the first time we've licensed our software for this length of
time, and it actually came at the request of the customer who has asked to
remain unnamed," said Ron Creeley, vice president of marketing and sales for
Simulations Plus. "The company had been a user of GastroPlus already, and their
CEO astutely realized that a multi-year license could provide a nice savings.
With this multi-year, multi-user license, the customer has enough licenses to
allow their staff to use GastroPlus for all of their oral drug projects without
having to compete for access to the software among groups. We are aggressively
pursuing additional multi-year, multi-user licenses for our software, including
our ADME Partners program announced earlier this year."
"Multi-year, multi-user licenses are a win-win situation for both Simulations
Plus and our customers. We receive cash up front to finance growth, and our
customers receive a nice discount for a product they have come to depend on in
their research," said Momoko Beran, chief financial officer of the Company.
"This sale has helped to push this quarter to yet another new record, and it
means that the fiscal year, which ends on August 31, is also another record
year. We will release preliminary fiscal year revenue numbers as soon as
possible -- probably next week. Earnings take more time to determine because we
must complete a combination of inventory, bank account reconciliation, and other
time-consuming activities. I hope to provide a reasonably accurate earnings
estimate for the fiscal year some time in October. In the meantime, we have
already announced earnings of $0.10 per share for the first three quarters, and
profits this quarter will provide a nice increase to that number."
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery
and development simulation software, which is licensed to and used in the
conduct of drug research by major pharmaceutical and biotechnology companies
worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM),
which are based on its proprietary software technologies. Simulations Plus,
Inc., is headquartered in Southern California and trades on the OTCBB under the
symbol "SIMU.OB." |
